Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (Nasdaq: TNGX) is a clinical-stage biopharmaceutical company developing precision cancer medicines through a synthetic lethality approach, using functional genomics and CRISPR-based screening to identify and exploit genetic vulnerabilities in tumor cells. The company accessed public markets in 2021 through a business combination with BCTG Acquisition Corp., a blank-check vehicle that completed its IPO in 2020 and was sponsored by BCTG Management LLC. The S-1 registration statement filed on September 10, 2021 was submitted in connection with securities issued as part of that de-SPAC transaction. Tango's pipeline spans multiple oncology indications in the precision medicine sector. Sign up on SpacDesk for full filing history, sponsor profiles, and deal timelines across the entire SPAC market.